Daraxonrasib median OS 13.2 months vs. 6.7 for chemotherapy. Phase 3 randomized controlled trial. I'm so happy.

ir.revmed.com/news-release...

Cap-independent translation by 4E-BP1, eIF4E, eIF4GI-eIF4A

Differential regulation of CITE-like (4EBP1-sensitive, HIF1α, p53A) versus IRES-like mechanisms (4EBP1-resistant, FGF9, p53B)

Fluorescence Anisotropy for protein-RNA binding

#JBC 2025
www.jbc.org/article/S002...

EPA reverses long-standing climate change finding, stripping its own ability to regulate emissions The agency announced it is repealing its 2009 conclusion that greenhouse gases warm the Earth and endanger human health and well-being.

EPA - Environmental Pollution Agency.
Oh, how far we have fallen.

www.nbcnews.com/science/clim...

Trump Allies Near ‘Total Victory’ in Wiping Out U.S. Climate Regulation

Pretty good summary of the forces arrayed against the CO2 endangerment finding. I think they are counting their chickens prematurely.

🎁 www.nytimes.com/2026/02/09/c...

Fluorescent microscopy image of cells from Lam et al, Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function, Cancers, 2026

Very excited to share a new research article from my lab about the biology of EGFR glycosylation that was published in the journal Cancers today. Congrats to all the authors!
www.mdpi.com/3706608

The New York Research and Mentoring for Postbaccalaureates (NY-RaMP) at Hunter College logo shows connections between the fields of bioinformatics, cell biology, microbiology, biochemistry, chemical biology, and molecular biology in the style of a New York City subway map.

The New York Research and Mentoring for Postbaccalaureates (NY-RaMP) program is recruiting! If you are a current college senior or recent graduate interested in 1 year of paid scientific research in NYC, more info about NY-RaMP and the application due on Feb 18 is available at nyramp.org

Jobs | City University of New York

Hunter College’s Department of Biological Sciences has a new open rank faculty search: cuny.jobs/new-york-ny/...

Sign the Petition Support a New York State Biomedical Institute for a Healthier, More Affordable Future

📢 SIGN & SHARE THE PETITION! 📢

New York needs an Empire Biomedical Research Institute to create new statewide funding opportunities for scientists & physician-scientists so that patients and their families get the life-saving and life-changing new therapeutics they're hoping for ✏️ c.org/TDMy2H9JTW

Exciting new finding about the role of PP2A molecular glues in overcoming resistant to broad classes of MAPK inhibitors in KRAS driven cancers
JCI - A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer www.jci.org/articles/vie...

Huge congrats to this year’s cohort of @damonrunyon SPARK postbacs -- especially @huntercollege alumni Subyeta Chowdhury and NY-RaMP alumni Imani Williams! damonrunyon.org/news/entries/8337/Damon%20Runyon%20announces%20newest%20class%20of%20SPARK%20Scholars

Damon Runyon mentor-mentee duo Piro Lito, MD, PhD, and Antonio Cuevas-Navarro, PhD, have developed a new approach to treating RAS-driven cancers, such as colorectal and pancreatic. Rather than inhibiting the cancerous protein, their drug restores its natural function. Read more:

Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity KRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also...

Great stuff! Hunter College osteosarcoma researcher Shahana Mahajan has published a paper with new findings that have possible applications to many types of cancers. More: journals.plos.org/plosone/arti... #MihiCuraFuturi

See How E.V. Road Trips Went From Impossible to Easy (Gift Article) There are a lot more fast chargers than there used to be. Look up what that could mean for a route near you.

See How E.V. Road Trips Went From Impossible to Easy www.nytimes.com/interactive/...

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results - Nature Medicine In the final analysis of a phase 1 trial evaluating a lymph node-targeting mutant KRAS peptide vaccine combined with CpG in the adjuvant setting for patients with KRAS mutant pancreatic or colorectal ...

Encouraging phase 1 results of an off-the-shelf, lymph node targeted #cancer vaccine targeting common #KRAS mutations (G12D, G12R) in pancreatic and colorectal cancer from Elicio $ELTX, @mskcancercenter.bsky.social, @mdanderson.bsky.social‪‬, UCLA & clinical collabs

www.nature.com/articles/s41...

Congratulations to our @obenaufa.bsky.social on receiving the highly prestigious Dr. Josef Steiner Cancer Research Award 2025! 🎉

Read more in this interview with Anna: www.imp.ac.at/news/article...

Model of daraxonrasib action in osteosarcoma from Jung et al PLOS ONE 2025

I am thrilled that our findings about using the Ras inhibitor daraxonrasib against osteosarcoma were just published in PLOS ONE! Many congrats to my co-authors Okkeun Jung, Angelene Soto, and Shahana Mahajan. dx.plos.org/10.1371/jour...

The federal government’s demand of $1 billion from @UCLA would devastate the nation’s best public university, cut off life-saving care, halt tech and economic growth and reduce educational access.

Stand with UC to protect our vital mission: www.universityofcalifornia.edu/get-involved...

In Game-Changing Climate Rollback, E.P.A. Aims to Kill a Bedrock Scientific Finding

www.nytimes.com/2025/07/29/c...

Exciting work!

25 Colleges. One University.

@cuny.edu Research in Focus looks at the work of Hunter College’s Climatologist and Professor of Geography and Environmental Science, William Solecki, who shows how we can design our public spaces to mitigate global warming. Read about it here: www.cuny.edu/news/resilie...

Congratulations and bon voyage to Hunter College alumni Sajida Ahmed, Alison Juray, Andrew Loka, and Alp Doymaz, who will be traveling all over the world during the 2025 - 2026 academic year through the Fulbright Program! #HunterPride hunter.cuny.edu/news/four-fr...

Excited to share our recent work published in PNAS last week uncovering the molecular mechanisms of PARP inhibitor resistance in BRCA2-deficient metastatic castration-resistant prostate cancer (mCRPC). Check out our manuscript!

Wolfe Lab at Hunter College group photo Spring 2025

Our amazing lab team, Spring 2025! A huge congratulations to the lab members about to earn their undergraduate degree, finish their postbaccalaureate program, begin graduate school, and begin medical school.

Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine | PNAS RAS is the most frequently mutated oncogene in cancer. RAS proteins show high sequence similarities in their G-domains but are significantly differ...

Very excited that this work was published in PNAS today!
www.pnas.org/doi/10.1073/...

Transport and InsP8 gating mechanisms of the human inorganic phosphate exporter XPR1. Zhu Q, Yaggi MF, Jork N, Jessen HJ, and Diver MM. Nature Communications. Published online March 20, 2025.

Huge congratulations to Dr. Melinda Diver and her lab on the publication of this outstanding new study, "Transport and InsP8 gating mechanisms of the human inorganic phosphate exporter XPR1" in the journal Nature Communications today!
www.nature.com/articles/s41...

The RNA-binding protein IMP2 reads m6A modifications to regulate target RNAs. When IMP2 changes, the many RNAs that it regulates change too, like a spider vibrating the strands of its web.

I am thrilled that our review about the RNA-binding protein IMP2 was published today! Congratulations to my co-authors Jessica Das, Ottavia Busia-Bourdain, and Khizr Khan.
doi.org/10.3390/ijms...

Nonopioid drug for acute pain wins FDA approval Ongoing trials will reveal whether suzetrigine is also effective against chronic pain

A long-awaited nonopioid pain drug has won approval from the U.S. Food and Drug Administration (FDA) to treat moderate to severe short-term pain.

KRAS Oncoprotein Signaling in Cancer | NEJM Recent studies provide new insights into signaling by mutant KRAS, inhibitors of which have provided modest benefits for patients.

Recent studies provide new insights into signaling by mutant KRAS, inhibitors of which have provided modest benefits for patients. Learn more in a new Clinical Implications of Basic Research article: nej.md/4aia1Bv

#MedSky #Oncology

A new post in Science Careers for our open-rank faculty search at the Hunter College Dept of Biological Sciences: jobs.sciencecareers.org/job/668588/o...

It's been a delight to be a Mentor to a Postbac Scholar in Damon Runyon SPARK this year. College seniors interested in paid full time cancer research next year - I encourage you to apply to SPARK. @damonrunyon.org damonrunyon.org/for-scientists/application-guidelines/research